TRANSFORMING VISIONS INTO SCIENCE

LAB BENCH-TO-MARKET
EVERYTHING UNDER ONE ROOF

MEDICINE AS UNIQUE AS YOU

BioNTech – Medicines as Unique as You

We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.

BioNTech in the News

BioNTech Congratulates CEO and Co-founder Prof. Ugur Sahin on German Cancer Award 2019

28th February 2019

BioNTech to Acquire Antibody Generation Unit of MAB Discovery

23rd January 2019

BioNTech Announces Corporate Form Transition from AG to SE

4th January 2019

Sanofi Invests EUR 80m in BioNTech as Partners Extend Collaboration

4th January 2019

BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration

5th November 2018

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

16th August 2018

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

10th July 2018

BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer

29th May 2018

BioNTech Secures USD 270 Million in Series A Financing

4th January 2018

BioNTech to Present at 36th Annual J.P. Morgan Healthcare Conference

21st December 2017

BioNTech Honored as WuXi AppTec Biotech Company of the Year at Scrip Awards 2017

30th November 2017

Research & Technology

BioNTech develops tailored treatments for cancer and other diseases with high unmet medical need through its world-class science and disruptive research platforms:

Partnering

BioNTech’s commercial strategy is to collaborate with selected partners that have a similar drive and commitment in developing and commercializing truly innovative and disruptive immunotherapies.

Pipeline

BioNTech develops and commercializes a broad product pipeline using different scientific approaches and cutting-edge technology platforms. BioNTech´s clinical pipeline represents a number of industry firsts.